

Growth Inhibitory Activity of Honokiol through Cell-cycle Arrest, Apoptosis and Suppression of Akt/mTOR Signaling in Human Hepatocellular Carcinoma Cells[†]

Ji-Young Hong¹, Hyen Joo Park¹, KiHwan Bae², Sam Sik Kang¹, and Sang Kook Lee^{1,*}

¹College of Pharmacy, Seoul National University, Seoul 151-742, Republic of Korea

²College of Pharmacy, Chungnam National University, Daejeon 305-764, Republic of Korea

Abstract – Honokiol, a naturally occurring neolignan mainly found in *Magnolia* species, has exhibited a potential anti-proliferative activity in human cancer cells. However, the growth inhibitory activity against hepatocellular carcinoma cells and the underlying molecular mechanisms has been poorly determined. The present study was designed to examine the anti-proliferative effect of honokiol in SK-HEP-1 human hepatocellular cancer cells. Honokiol exerted anti-proliferative activity with cell-cycle arrest at the G0/G1 phase and sequential induction of apoptotic cell death. The cell-cycle arrest was well correlated with the down-regulation of checkpoint proteins including cyclin D1, cyclin A, cyclin E, CDK4, PCNA, retinoblastoma protein (Rb), and c-Myc. The increase of sub-G1 peak by the higher concentration of honokiol (75 μ M) was closely related to the induction of apoptosis, which was evidenced by decreased expression of Bcl-2, Bid, and caspase-9. Honokiol was also found to attenuate the activation of signaling proteins in the Akt/mTOR and ERK pathways. These findings suggest that the anti-proliferative effect of honokiol was associated in part with the induction of cell-cycle arrest, apoptosis, and down-regulation of Akt/mTOR signaling pathways in human hepatocellular cancer cells.

Keywords – Honokiol, G0/G1 Cell-cycle arrest, Apoptosis, Akt/mTOR, SK-HEP-1 cells.

Introduction

Hepatocellular carcinoma is one of the most fatal cancers and ranked as the third cause of cancer-associated deaths in the world (Hussain *et al.*, 2001; Bosch *et al.*, 2004). Along with surgery and radiotherapy, chemotherapy is one of the most common strategy in hepatocellular cancer therapy, (Nagano, 2010). However, conventional anticancer drugs for hepatocellular carcinoma are typically non-selective cytotoxic molecules with significant systemic unexpected effects. Therefore, it is important to develop more safer and effective therapeutic agents for hepatocellular cancer cells.

Honokiol is a natural component mainly found in *Magnolia obovata* (family Magnoliaceae) (Cui *et al.*, 2007; Han *et al.*, 2007). In recent study, various biological activities of honokiol including anti-inflammation, anti-oxidant, neurotoxicity, angiopathy, thrombosis, anti-proliferative effects in various cancer cells have been

reported (Cui *et al.*, 2007; Fried and Arbiser, 2009; Shen *et al.*, 2010; Tian *et al.*, 2012; Zhang *et al.*, 2013). In our recent study, we reported that the growth inhibition of breast cancer cells by honokiol was associated with the cell cycle arrest, apoptosis and down-regulation of c-Src/EGFR-mediated cell signaling pathway (Park *et al.*, 2009). In addition, we also found that honokiol induced cell cycle arrest and apoptosis in human gastric cancer cells (Kang *et al.*, 2012). Although the anti-proliferative activity of honokiol has been reported in various cancer cells, the underlying mechanisms of action remain to be clarified in hepatocellular cancer cells.

Herein, we report for the first time that honokiol exhibits anti-proliferative activity in human SK-HEP-1 human hepatocellular cancer cells, which was associated with G0/G1 cell-cycle arrest, apoptosis and the suppression of Akt/mTOR signaling pathways.

Experimental

Chemicals – Trichloroacetic acid (TCA), sulforhodamine B, propidium iodide, trypsin inhibitor, RNase A, and anti- β -actin primary antibody were purchased from Sigma (St.Louis, MO, USA). Rosewell Park Memorial Institute

[†]Dedicated to Prof. Sam Sik Kang of the Seoul National University for his leading works on Natural Products Research.

*Author for correspondence

Dr. Sang Kook Lee, College of Pharmacy, Seoul National University, San 56-1, Sillim-dong, Gwanak-gu, Seoul 151-742, Korea
Tel: +82-2-880-2475; E-mail: sklee61@snu.ac.kr

medium 1640 (RPMI 1640), fetal bovine serum (FBS), non-essential amino acid solution (10 mM, 100X), trypsin-EDTA solution (1X) and antibiotic-antimycotic solution (PSF) were from GIBCO-BRL (Grand Island, NY, USA). Rabbit polyclonal anti-CDK4, anti-cyclin A, anti-cyclin D1, anti-PCNA, anti-cMyc, anti-Bcl-2, anti-ERK, anti-phospho ERK antibody, horseradish peroxidase (HRP)-conjugated anti-mouse IgG, and horseradish peroxidase (HRP)-conjugated anti-rabbit IgG were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse anti-phospho-Rb (Ser 807/811), anti-Rb, anti-Bid, anti-caspase-9, anti-phospho-Akt (Ser473), anti-Akt, anti-phospho-mTOR (Ser2448), anti-mTOR antibody were obtained from Cell Signaling (Danvers, MA, USA). Mouse monoclonal anti-cyclin E was from BD Biosciences (San Diego, CA, USA). Honokiol isolated from the bark of *Magnolia obavata* was provided from Dr. KiHwan Bae (Chungnam National University, Korea).

Cell culture – Human hepatocellular carcinoma SK-HEP-1 cells, obtained from the Korean Cell Line Bank (Seoul, Korea), were cultured in RPMI supplemented with 10% heat-inactivated fetal bovine serum, 100 units/mL penicillin, 100 µg/mL streptomycin, and 250 ng/mL amphotericin B. Cells were maintained at 37 °C in humidified atmosphere with 5% CO₂.

Evaluation of growth inhibitory potential – SK-HEP-1 cells (5×10^4 cells/mL) were treated with various concentrations of test compound for 3 days. After treatment, cells were fixed with 10% TCA solution, and cell proliferation was determined with sulforhodamine B (SRB) protein staining method (Jo *et al.*, 2012). The result was expressed as a percentage, relative to solvent-treated control incubations, and the IC₅₀ values were calculated using non-linear regression analysis (percent survival versus concentration).

Analysis of cell cycle dynamics by flow cytometry – Cell cycle analysis by flow cytometry was performed as previously described (Kang *et al.*, 2009). Briefly, SK-HEP-1 cells were plated at a density of 1×10^6 cells per 100-mm culture dish and incubated for 24 h. Fresh media containing test samples were added to culture dishes. After 24 h, the cells were harvested (trypsinization and centrifugation), fixed with 70% ethanol, and incubated with a staining solution containing 0.2% NP-40, RNase A (30 µg/mL), and propidium iodide (50 µg/mL) in phosphate-citrate buffer (pH 7.2). Cellular DNA content was analyzed by flow cytometry using a Becton Dickinson laser-based flow cytometer. At least 20,000 cells were used for each analysis, and results were displayed as histograms of DNA content. The distribution

of cells in each phase of cell cycle was calculated using ModFit LT2.0 program.

Evaluation of the protein expression by Western blot – SK-HEP-1 human hepatocellular carcinoma cells were exposed with various concentrations of honokiol for 24 h. After incubation, cells were lysed and protein concentrations were determined by BCA method. Each protein (40 µg) was subjected to SDS-PAGE. Proteins were transferred onto PVDF membranes by electroblotting, and membranes were treated for 1 h with blocking buffer [5% non-fat dry milk in phosphate-buffered saline-0.1% Tween 20 (PBST)]. Membranes were then incubated with indicated antibodies (mouse anti-β-actin, diluted 1 : 2,000; other antibodies, diluted 1 : 1,000 in PBST) overnight at 4 °C, washed three times for 5 min with PBST. After washing, membranes were incubated with HRP-conjugated anti-mouse IgG diluted 1 : 2,000 in PBST for 2 h at room temperature, washed three times for 5 min with PBST, and visualized by HRP-chemiluminescent detection kit (Lab Frontier, Seoul, Korea) using LAS-3000 Imager (Fuji Film Corp., Japan) (Kang *et al.*, 2012).

Statistical analysis – Data were presented as means ± SE for the indicated number of independently performed experiments. Statistical significance ($p < 0.05$) was assessed by one-way analysis of variance (ANOVA) coupled with Dunnett's t-tests.

Results and Discussion

To determine the effects of honokiol on the growth of human hepatocellular cancer cells, its growth inhibitory potential was evaluated by a colorimetric sulforhodamine B (SRB) protein dye staining method. As shown Fig. 1, honokiol exhibited potent growth inhibition of SK-HEP-1 human hepatocellular cancer cells with the IC₅₀ value of 44.1 µM. In particular, cells exposed to the highest concentration (100 µM) exerted remarkable decrease in cell survival. Morphological changes by treatment with honokiol were also examined using phase-contrast microscopy. Following treatment with honokiol (25, 50, and 75 µM), the number of cells were decreased compared to control cells, and especially, floating cells were observed when treated with 75 µM indicating that cell death was induced. As shown in Fig. 2, cells treated with honokiol exhibited morphological changes with distinct rounded shapes and detachment in a time- and concentration-dependent manner when compared to vehicle-treated control cells.

Cell proliferation is generally controlled by the progression of three distinctive phases (G₀/G₁, S, and G₂/




Fig. 1. Effect of honokiol on the proliferation of SK-HEP-1 human hepatocellular cancer cells. SK-HEP-1 cells were plated at 10,000 cells in 96-well plate in RPMI supplemented with 10% FBS, and incubated with the test compound as the indicated concentrations for 3 days. Anti-proliferative effect was determined using SRB assay. The values of % cell growth are calculated by the mean absorbance of samples/absorbance of vehicle-treated control. Data are represented as the means \pm S.E. (n = 3).




Fig. 2. Morphological changes mediated by honokiol in SK-HEP-1 cells. Cells were treated with or without various concentrations of honokiol for 24 h. Cells were photographed by inverted microscopy (magnification 100 \times).

M) of the cell cycle, and cell-cycle arrest is considered one of the most common causes of the inhibition of cell proliferation (Kastan and Bartek, 2004). To investigate whether honokiol could affect the cell cycle regulation, flow cytometric analysis was performed after staining cells with propidium iodide. As shown in Fig. 3, treatment of honokiol resulted in a considerable accumulation of cells




Fig. 3. Effect of honokiol on the regulation of cell cycle distribution in SK-HEP-1 cells. Cells were seeded at 1×10^6 cells in 100 mm dish in RPMI supplemented with 10% FBS, and then treated with various concentration of honokiol for 24 h. The cell cycle distribution was analyzed by flow cytometry as described in Materials and Methods.

in the G0/G1 phase (25 μ M; 64.0%, 50 μ M; 78.1%) by up to 31% increase in comparison with the distribution of control cells. However, the treatment of higher concentration of honokiol (75 μ M) subsequently increased the sub-G1 phase, indicative of apoptotic peaks. These data show that honokiol induces cell-cycle arrest in the G0/G1 phases at 25 and 50 μ M concentration and induction of cell death at 75 μ M, a relatively high concentration.

Further study was designed to examine the effect of honokiol on the expression of cell cycle regulatory proteins associated with G0/G1 cell-cycle arrest by Western blot analysis. Honokiol suppressed the protein expression of checkpoint proteins such as cyclin D1, CDK4 and PCNA, and also down-regulated the expression of biomarkers such as cyclin A and E in the transition of G1 to S phase in a concentration-dependent manner (Fig. 4A). Since these proteins are known to form active complexes of cyclin-CDK, and mediate the inactivation of Rb tumor suppressor protein, the level of the phosphorylation of Rb was determined (Schwartz and Shah, 2005). As a result, both the phosphorylated- and total Rb were suppressed by honokiol. In addition, the expression of c-Myc, an oncoprotein that causes the cell cycle progression (Pelengaris *et al.*, 2002), was markedly down-regulated in cells treated with honokiol compared with control cells. To further study the apoptotic




Fig. 4. Effect of honokiol on the expression of cell cycle (A) and apoptosis (B)-associated proteins in SK-HEP-1 cells. Cells were treated with the indicated concentrations of honokiol for 24 h. The expression level of proteins was analyzed by Western blot.

mechanisms underlying the cytotoxic activities of honokiol, the effects of honokiol on the expression of Bcl-2, Bid and procaspase-9 were examined. As shown in Fig 4B, honokiol suppressed the expression of Bcl-2 and Bid, antiapoptotic proteins, and caspase-9, and these events subsequently affect to the induction of apoptosis.

Further study was conducted to determine whether the anti-proliferative effect of honokiol was associated with the regulation of the cell signaling transduction pathway. The Akt and mammalian target of rapamycin (mTOR) has been known to be one of the main signaling pathways to regulate cell proliferation, growth, differentiation, and survival (Wullschleger *et al.*, 2006; Alexander *et al.*, 2010). The abnormal activation of these pathways is frequently found in various cancer cells including hepatocellular carcinoma (Kudo, 2011; Zhou *et al.*, 2011). Therefore, targeting Akt/mTOR signaling pathway is considered a promising approach for cancer management (Wullschleger *et al.*, 2006). To investigate whether honokiol is able to affect the regulation of Akt/mTOR signaling pathway, the expression levels of the phosphorylated form of Akt and mTOR were evaluated. As shown in Fig. 5, honokiol remarkably suppressed the expression of phosphorylated Akt and mTOR. In addition, honokiol down-regulated the expression of phosphorylated ERK, which is considered one of key mechanisms for promoting cell cycle progression and cell proliferation. Therefore, the down-regulation of Akt/mTOR and ERK signaling might be in part associated with the anti-proliferative effect of honokiol in SK-HEP-1 cells.

In conclusion, the present study revealed that honokiol is a potent inhibitor of the growth of human hepatocellular cancer cells, and the growth inhibition is correlated with cell-cycle arrest and induction of apoptosis. The growth inhibition is also associated with the modulation of signal



Fig. 5. Effects of honokiol on the expression of signal transduction proteins. SK-HEP-1 cells were treated for 24 h with various concentration of honokiol and the protein expressions were measured by Western blot analysis.

transduction pathway in the Akt/mTOR signaling. The results demonstrate that honokiol might have a therapeutic potential in the management of human hepatocellular cancer cells.

Acknowledgements

This study was supported by a grant Studies on the Identification of the Efficacy of Biologically Active Components from Oriental Herbal Medicines from the Korea Food and Drug Administration (2006 and 12172KFDA989).

References

- Alexander, A., Cai, S.L., Kim, J., Nanez, A., Sahin, M., MacLean, K.H., Inoki, K., Guan, K.L., Shen, J., Person, M.D., Kusewitt, D., Mills, G.B., Kastan, M.B., and Walker, C.L., ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 4153-4158 (2010).
- Bosch, F.X., Ribes, J., Díaz, M., and Cléries, R., Primary liver cancer: worldwide incidence and trends. *Gastroenterology* **127**, S5-S16 (2004).
- Cui, H.S., Huang, L.S., Sok, D.E., Shin, J., Kwon, B.M., Youn, U.J., and Bae, K., Protective action of honokiol, administered orally, against oxidative stress in brain of mice challenged with NMDA. *Phytomedicine* **14**, 696-700 (2007).
- Fried, L.E. and Arbiser, J.L., Honokiol, a multifunctional antiangiogenic and antitumor agent. *Antioxid. Redox Signal.* **11**, 1139-1148 (2009).
- Han, S.J., Bae, E.A., Trinh, H.T., Yang, J.H., Youn, U.J., Bae, K.H., and Kim, D.H., Magnolol and honokiol: inhibitors against mouse passive cutaneous anaphylaxis reaction and scratching behaviors. *Biol. Pharm. Bull.* **30**, 2201-2203 (2007).
- Hussain, S.A., Ferry, D.R., EL-Gazzaz, G., Mirza, D.F., James, N.D., McMaster, P., and Kerr, D.J., Hepatocellular carcinoma. *Ann. Oncol.* **12**, 161-172 (2001).

- Jo, S.K., Hong, J.Y., Park, H.J., and Lee, S.K., Anticancer activity of novel daphnane diterpenoids from *Daphne genkwa* through cell-cycle arrest and suppression of Akt/STAT/Src signaling in human lung cancer cells. *Biomol. Ther.* **20**, 513-519 (2012).
- Kang, Y.J., Chung, H.J., Min, H.Y., Song, J., Park, H.J., Youn, U.J., Bae, K.H., Kim, Y.S., and Lee, S.K., G0/G1 cell cycle arrest and activation of caspases in honokiol-mediated growth inhibition of human gastric cancer cells. *Nat. Prod. Sci.* **18**, 16-21 (2012).
- Kang, Y.J., Min, H.Y., Hong, J.Y., Kim, Y.S., Kang, S.S., and Lee, S.K., Ochnaflavone, a natural biflavonoid, induces cell cycle arrest and apoptosis in HCT-15 human colon cancer cells. *Biomol. Ther.* **17**, 282-287 (2009).
- Kastan, M.B. and Bartek, K., Cell-cycle checkpoints and cancer. *Nature* **432**, 316-323 (2004).
- Kudo, M., mTOR inhibitor for the treatment of hepatocellular carcinoma. *Dig. Dis.* **29**, 310-315 (2011).
- Nagano, H., Treatment of advanced hepatocellular carcinoma: intraarterial infusion chemotherapy combined with interferon. *Oncology* **78**, 142-147 (2010).
- Park, E.J., Min, H.Y., Chung, H.J., Hong, J.Y., Kang, Y.J., Hung, T.M., Youn, U.J., Kim, Y.S., Bae, K.H., Kang, S.S., and Lee, S.K., Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells. *Cancer Lett.* **227**, 133-140 (2009).
- Pelengaris, S., Khan, M., and Evan, G., c-Myc: more than just a matter of life and death. *Nat. Rev. Cancer* **2**, 764-776 (2002).
- Schwartz, G.K. and Shah, M.A., Targeting the cell cycle: a new approach to cancer therapy. *J. Clin. Oncol.* **23**, 9408-9421 (2005).
- Shen, J.L., Man, K.M., Huang, P.H., Chen, W.C., Chen, D.C., Cheng, Y.W., Liu, P.L., Chou, M.C., and Chen, Y.H., Honokiol and magnolol as multifunctional antioxidative molecules for dermatologic disorders. *Molecules* **15**, 6452-6465 (2010).
- Tian, W., Xu, D., and Deng, Y.C., Honokiol, a multifunctional tumor cell death inducer. *Pharmazie* **67**, 811-816 (2012).
- Wullschleger, S., Loewith, R., and Hall, M.N., TOR signaling in growth and metabolism. *Cell* **124**, 471-484 (2006).
- Zhang, P., Liu, X., Zhu, Y., Chen, S., Zhou, D., and Wang, Y., Honokiol inhibits the inflammatory reaction during cerebral ischemia reperfusion by suppressing NF- κ B activation and cytokine production of glial cells. *Neurosci. Lett.* **8**, 123-127 (2013).
- Zhou, G., Lui, V.W., and Yeo, W., Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. *Future Oncol.* **7**, 1149-1167 (2011).

Received May 26, 2013

Revised June 18, 2013

Accepted June 20, 2013